

AMENDMENT

It is respectfully requested that the claims be amended without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

In The Claims:

1. (Currently Amended) A method for treating a disorder characterized by excessive proliferation of tissue treatable by thrombospondin-2 (TSP-2) or a fragment thereof, in a subject in need thereof comprising implanting a cell-matrix structure, wherein said cell-matrix structure comprises a matrix having attached thereto cells that stably express TSP-2, or a fragment thereof wherein the fragment comprises at least 10 contiguous amino acids of ~~either~~ (a) a procollagen domain of TSP-2, or (b) a Type I repeat of TSP-2, in an amount effective to inhibit or regress the excessive tissue proliferation.
2. (Previously presented) The method of claim 1 wherein the disorder is selected from the group consisting of malignant and benign neoplasias, vascular, inflammatory conditions causing excessive proliferation of cells, endometriosis, unwanted skin proliferation, unwanted angiogenesis of the eye, restenosis, and infections causing excessive proliferation of cells.
3. (Original) The method of claim 1 wherein the matrix is selected from the group consisting of fibrous scaffolds, polymeric hydrogels, and micromachine or micromolded substrates.
4. (Original) The method of claim 1 wherein the cells are selected from the group consisting of fibroblasts, tissue specific cells, progenitor cells, and stem cells.
5. (Previously presented) The method of claim 1 wherein the cells are genetically engineered to produce TSP-2 or a fragment thereof.

6. (Canceled)

7. (Previously presented) The method of claim 1 wherein TSP-2 or a fragment thereof is endogenous to the cells on the matrix and the cells are engineered to increase expression of TSP-2 or a fragment thereof.

8-21. (Canceled)

22. (Previously presented) The method of claim 1 wherein the cells are of a different cell type than the tissue that has proliferated.

23. (Previously presented) The method of claim 1 wherein the cells are selected based on natural production of TSP-2 or a fragment thereof.

24-29. (Canceled)